



PARTICIPANT STATISTICS

SECOND QUADRIMESTER 2018

ANTINUCLEAR ANTIBODY

Antinuclear Screen

IFA	Specimen 1		Specimen 2		Specimen 3		Specimen 4		Specimen 5	
	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos
Bio-Rad Microplate EIA HEp-2	3			3	3			3		3
Zeus HEp-2	3			3	3			3		3
Total Population	8	0	0	8	8	0	0	8	0	8
Flagging		***	***			***	***		***	

ELISA or IA	Specimen 1		Specimen 2		Specimen 3		Specimen 4		Specimen 5	
	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos
High Specificity										
DiaMedix EIA	4		4		4			4		4
GenBio ImmunoDOT EIA Panel	2		2		2			2		2
Total Population	6	0	6	0	6	0	0	6	0	6
Flagging		***		***		***	***		***	
High Sensitivity										
Wampole ANA Scrn ELISA	3		2	1	3			3		3
Total Population	3	0	2	1	3	0	0	3	0	3
Flagging		***				***	***		***	

*Due to a lack of participant consensus, Specimen 2 was not evaluated for High Sensitivity methods..

anti-ENA	Specimen 1		Specimen 2		Specimen 3		Specimen 4		Specimen 5	
	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos
ASI SLE latex agglutination	23			23	23		2	21	23	
Diagnostic Tech ANA-Check	5			5	5			5	5	
Total Population	28	0	0	28	28	0	2	26	28	0
Flagging		**	***			***	***			***

Multiplex Algorithm Based	Specimen 1		Specimen 2		Specimen 3		Specimen 4		Specimen 5	
	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos
Bio-Rad Bioplex 2200	9		8	1	8	1		9	1	8
Total Population	9	0	8	1	8	1	0	9	1	8
Flagging		***		***		***	***		***	

Anti-DNA

Anti-dsDNA	Specimen 1		Specimen 2		Specimen 3		Specimen 4		Specimen 5	
	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos
Bio-Rad BioPlex, 2200	5		5		5		5		5	
GenBio ImmunoDOT EIA Panel	2		2		2		2		2	
Total Population	16	0	15	1	16	0	16	0	14	2
Flagging		***		***		***		***		***

Anti-RNP	Specimen 1		Specimen 2		Specimen 3		Specimen 4		Specimen 5	
	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos
Bio-Rad BioPlex, 2200	5		5		5		5		5	
Total Population	7	0	7	0	7	0	5	2	7	0
Flagging		***		***		***				***

*Due to a lack of participant consensus, Specimen 4 was not evaluated.

Anti-Sm	Specimen 1		Specimen 2		Specimen 3		Specimen 4		Specimen 5	
	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos
Bio-Rad BioPlex, 2200	6		6		6		6		6	
Total Population	11	0	11	0	11	0	11	0	11	0
Flagging		***		***		***		***		***

Anti-RNP/Sm	Specimen 1		Specimen 2		Specimen 3		Specimen 4		Specimen 5	
	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos
Bio-Rad BioPlex, 2200	6		6		6		1	5	6	
GenBio ImmunoDOT EIA Panel	2		2		2		1	1	1	1
Total Population	11	0	11	0	11	0	2	9	10	1
Flagging		***		***		***	***			***

Anti-SSA	Specimen 1		Specimen 2		Specimen 3		Specimen 4		Specimen 5	
	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos
Bio-Rad BioPlex, 2200	6		6		5	1	5	1	1	5
Total Population	10	0	10	0	9	1	9	1	1	9
Flagging		***		***		***		***	***	

Anti-SSB	Specimen 1		Specimen 2		Specimen 3		Specimen 4		Specimen 5	
	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos
Bio-Rad BioPlex, 2200	6		6		5	1	5	1	1	5
Total Population	9	0	9	0	8	1	8	1	1	8
Flagging		***		***		***		***	***	

Anti-SSA/SSB	Specimen 1		Specimen 2		Specimen 3		Specimen 4		Specimen 5	
	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg	Pos
GenBio ImmunoDOT EIA Panel	2		2		2		1	1	1	1
Total Population	2	0	2	0	2	0	1	1	1	1
Flagging		***		***		***				

*Due to a lack of participant consensus, Specimens 4 and 5 were not evaluated.

ANA Florescence Pattern	No.	Flagging
Specimen 1		
Negative	3	
Negative, normal background flo	4	
Specimen 2		
Homogenous/Diffuse	5	
Speckled	1	
Negative	1	***
Specimen 3		
Negative, normal background flo	4	
Negative	2	
Speckled	1	***
Specimen 4		
Speckled	6	
Centromere	1	***
Specimen 5		
Speckled	4	
Homogenous/Diffuse	2	
Negative	1	***

Correct responses are defined as those reflecting agreement among 80% or more of all participants or referees. Unacceptable responses are indicated by "*****" on the Flagging line of each specimen.